The Patent Finder

Idec Pharmaceuticals Corporation

Also on record
Records under this name other than patents Idec Pharmaceuticals Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Idec Pharmaceuticals Corporation

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 7,157,276Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
Formerly held
Term ended
Term ended Jun 21, 2024 · USPTO record
Term endedTerm ended Jun 21, 2024USPTO record
US 7,220,356Method of Purifying Polypeptides by Simulated Moving Bed Chromatography
Formerly held
Term ended
Term ended Sep 12, 2023 · High confidence
Term endedTerm ended Sep 12, 2023High confidence
US 7,319,139TAG-72 specific CH2 domain deleted antibodies
Formerly held
Term ended
Term ended Jan 29, 2022 · USPTO record
Term endedTerm ended Jan 29, 2022USPTO record
US 8,329,172Combination therapies for B-cell lymphomas comprising administration of anti-CD20 antibody
Formerly held
Term ended
Term ended Nov 15, 2021 · USPTO record
Term endedTerm ended Nov 15, 2021USPTO record
US 7,604,989Inhibition of apoptosis process and improvement of cell performance
Formerly held
Lapsed on the fee record
Ended Oct 20, 2021 · USPTO record
Lapsed on the fee recordEnded Oct 20, 2021USPTO record
US 7,294,753Method for Preparing Anti-Mif Antibodies
Formerly held
Term ended
Term ended Jun 3, 2021 · Medium confidence
Term endedTerm ended Jun 3, 2021Medium confidence
US 6,682,734Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
Formerly held
Term ended
Ended no later than Jan 27, 2021 · USPTO record
Term endedEnded no later than Jan 27, 2021USPTO record
US 8,557,244Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
Formerly held
Term ended
Ended no later than Jul 28, 2020 · USPTO record
Term endedEnded no later than Jul 28, 2020USPTO record
US 9,504,744Treatment of Diffuse Large-Cell Lymphoma with ANTI-CD20 Antibody
Formerly held
Term ended
Term ended Jul 28, 2020 · Medium confidence
Term endedTerm ended Jul 28, 2020Medium confidence
US 6,451,284Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy
Formerly held
Term ended
Term ended Jul 26, 2020 · USPTO record
Term endedTerm ended Jul 26, 2020USPTO record
10 of 81 patents shown.
Pro members see all 81.
Pro members: see all 81 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited